$2.07 Billion is the total value of Camber Capital Management LP's 48 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 45.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | New | SPDR S&P 500 ETF TRput | $209,480,000 | – | 1,000,000 | +100.0% | 10.12% | – |
| TEVA | Buy | TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR)adr | $144,160,000 | +19.7% | 2,870,000 | +27.6% | 6.97% | -1.2% |
| MYL | Buy | MYLAN NV | $118,478,000 | +38.2% | 2,740,000 | +48.1% | 5.73% | +14.0% |
| GILD | Buy | GILEAD SCIENCES, INC.call | $83,420,000 | +81.6% | 1,000,000 | +100.0% | 4.03% | +49.9% |
| ENDP | New | ENDO INT PLC | $78,652,000 | – | 5,045,000 | +100.0% | 3.80% | – |
| CSII | New | CARDIOVASCULAR SYSTEMS INC | $75,338,000 | – | 4,100,000 | +100.0% | 3.64% | – |
| MDCO | Sell | MEDICINES COMPANY | $67,260,000 | -15.3% | 2,000,000 | -20.0% | 3.25% | -30.1% |
| BIIB | Buy | BIOGEN IDEC INC | $66,501,000 | +46.0% | 275,000 | +57.1% | 3.21% | +20.5% |
| CI | New | CIGNA CORP | $63,995,000 | – | 500,000 | +100.0% | 3.09% | – |
| GHDX | GENOMIC HEALTH INC | $63,652,000 | +4.5% | 2,458,100 | 0.0% | 3.08% | -13.7% | |
| OFIX | ORTHOFIX INTL N V | $63,600,000 | +2.1% | 1,500,000 | 0.0% | 3.07% | -15.7% | |
| GILD | New | GILEAD SCIENCES, INC. | $62,565,000 | – | 750,000 | +100.0% | 3.02% | – |
| BKD | Sell | BROOKDALE SENIOR LIVING | $61,760,000 | -22.2% | 4,000,000 | -20.0% | 2.98% | -35.8% |
| SEM | SELECT MEDICAL HOLDINGS CORP | $60,600,000 | -8.0% | 5,575,000 | 0.0% | 2.93% | -24.0% | |
| NKTR | Sell | NEKTAR THERAPEUTICS | $60,478,000 | -2.3% | 4,250,000 | -5.6% | 2.92% | -19.3% |
| LIVN | LIVANOVA PLC | $60,276,000 | -6.9% | 1,200,000 | 0.0% | 2.91% | -23.2% | |
| TEVA | Buy | TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR)call | $56,509,000 | +5.6% | 1,125,000 | +12.5% | 2.73% | -12.9% |
| PRGO | New | PERRIGO CO PLC | $51,682,000 | – | 570,000 | +100.0% | 2.50% | – |
| LDRH | Sell | LDR HOLDING CORP | $50,806,000 | -11.4% | 1,375,000 | -38.9% | 2.46% | -26.9% |
| ABC | New | AMERISOURCEBERGEN CORP | $49,575,000 | – | 625,000 | +100.0% | 2.40% | – |
| NUVA | Sell | NUVASIVE INC. | $44,790,000 | -38.6% | 750,000 | -50.0% | 2.16% | -49.3% |
| UAM | UNIVERSAL AMERICAN CORPORATION | $44,533,000 | +6.2% | 5,875,000 | 0.0% | 2.15% | -12.4% | |
| WMGI | Buy | WRIGHT MEDICAL GROUP NV | $42,991,000 | +78.3% | 2,475,000 | +70.4% | 2.08% | +47.2% |
| CYH | New | COMMUNITY HEALTH SYS INC NE COM | $41,573,000 | – | 3,450,000 | +100.0% | 2.01% | – |
| ALKS | New | ALKERMES PLC | $40,510,000 | – | 937,300 | +100.0% | 1.96% | – |
| ELGX | Sell | ENDOLOGIX INC | $37,380,000 | +15.7% | 3,000,000 | -22.4% | 1.81% | -4.5% |
| VRX | Sell | VALEANT PHARMACEUTICALS INT (USA) | $33,352,000 | -36.6% | 1,656,000 | -17.2% | 1.61% | -47.7% |
| THC | Sell | TENET HEALTHCARE CORP THC | $31,095,000 | -28.3% | 1,125,000 | -25.0% | 1.50% | -40.9% |
| ARIA | Sell | ARIAD PHARMACEUTICALS INC | $29,560,000 | -14.4% | 4,000,000 | -26.0% | 1.43% | -29.4% |
| BIOS | Buy | BIOSCRIP INC | $25,959,000 | +96.3% | 10,180,000 | +64.7% | 1.26% | +62.1% |
| NVTA | INVITAE CORP | $20,298,000 | -27.8% | 2,746,622 | 0.0% | 0.98% | -40.4% | |
| ELOS | Buy | SYNERON MEDICAL LTD | $18,053,000 | +64.0% | 2,347,593 | +55.9% | 0.87% | +35.2% |
| ARNA | New | ARENA PHARMACEUTICALS INC | $17,955,000 | – | 10,500,000 | +100.0% | 0.87% | – |
| SQNM | SEQUENOM INC | $15,830,000 | -35.2% | 17,325,000 | 0.0% | 0.76% | -46.5% | |
| AMAG | AMAG PHARMACEUTICALS | $14,352,000 | +2.2% | 600,000 | 0.0% | 0.69% | -15.6% | |
| PTCT | Buy | PTC THERAPEUTICS | $10,530,000 | +82.9% | 1,500,000 | +67.8% | 0.51% | +51.0% |
| PLX | PROTALIX BIO THERAPEUTICS, INC | $8,496,000 | -23.9% | 13,275,000 | 0.0% | 0.41% | -37.1% | |
| DRRX | DURECT CORP COM | $7,320,000 | -9.6% | 6,000,000 | 0.0% | 0.35% | -25.3% | |
| BIOL | BIOLASE INC | $6,239,000 | -10.7% | 5,332,394 | 0.0% | 0.30% | -26.2% | |
| PROTALIX BIO THERAPEUTICS, INCnote 4.500% 9/1 | $6,113,000 | +1.9% | 9,000,000 | 0.0% | 0.30% | -16.0% | ||
| Sell | INNOCOLL AG | $5,836,000 | -38.8% | 1,059,139 | -4.7% | 0.28% | -49.5% | |
| GNMK | GENMARK DIAGNOSTICS | $5,647,000 | +65.1% | 649,097 | 0.0% | 0.27% | +36.5% | |
| OSUR | Sell | ORASURE TECHNOLOGIES INC | $4,182,000 | -71.1% | 707,559 | -64.6% | 0.20% | -76.2% |
| CATB | CATABASIS PHARMACEUTICALS INC | $3,700,000 | -26.6% | 1,000,000 | 0.0% | 0.18% | -39.3% | |
| TARGACEPT INCnote | $1,685,000 | 0.0% | 1,684,799 | 0.0% | 0.08% | -18.2% | ||
| DXTRQ | New | DEXTERA SURGICAL INC. | $1,507,000 | – | 837,483 | +100.0% | 0.07% | – |
| EPRSQ | EPIRUS BIOPHARMACEUTICALS | $835,000 | -83.2% | 1,847,500 | 0.0% | 0.04% | -86.3% | |
| BIOLASE INCcall | $4,000 | -81.8% | 1,841,173 | 0.0% | 0.00% | -100.0% | ||
| UNIS | Exit | UNILIFE CORP | $0 | – | -2,750,000 | -100.0% | -0.11% | – |
| ANGO | Exit | ANGIODYNAMICS INC. | $0 | – | -243,183 | -100.0% | -0.18% | – |
| CRDC | Exit | CARDICA INC | $0 | – | -837,483 | -100.0% | -0.18% | – |
| Exit | ARENA PHARMACEUTICALS INC | $0 | – | -10,500,000 | -100.0% | -1.21% | – | |
| MDVN | Exit | MEDIVATION INC. | $0 | – | -825,000 | -100.0% | -2.22% | – |
| ALKS | Exit | ALKERMES INC | $0 | – | -1,200,000 | -100.0% | -2.40% | – |
| MASI | Exit | MASIMO CORPORATION | $0 | – | -1,000,000 | -100.0% | -2.45% | – |
| Exit | CARDIOVASCULAR SYSTEMS INC | $0 | – | -4,100,000 | -100.0% | -2.49% | – | |
| DGX | Exit | QUEST DIAGNOSTICS INC | $0 | – | -600,000 | -100.0% | -2.51% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -900,000 | -100.0% | -3.01% | – |
| STJ | Exit | ST. JUDE MEDICAL, INC. | $0 | – | -1,250,000 | -100.0% | -4.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.